Pfizer Inc. and Acura Pharmaceuticals Inc. has announced the marketing approval from the US Food and Drug Administration (FDA) of Oxecta (oxycodone HCl, USP) tablets CII. Oxecta is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
Oxecta is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering associated with opioid abuse and misuse. This Aversion Technology is a unique composition of commonly used pharmaceutical ingredients. Pfizer is licensing the technology in Oxecta from Acura.
Opioid medications are an important treatment option for patients with moderate to severe pain who are not adequately managed by other pain treatments. However, abuse and misuse of opioids is a serious public health issue that is the focus of a number of recent United States government initiatives.
“We recognize our responsibility to physicians and patients and remain committed to appropriate access to pain treatment and developing medicines to potentially address this important public health and safety issue,” said Olivier Brandicourt, Pfizer president and general manager, Primary Care. “Oxecta will further expand Pfizer’s presence in pain management and complements our growing, robust portfolio of treatments and medicines in development for pain relief, one of our strategic, high-priority disease areas. We are pleased to bring Oxecta to patients and physicians with our partner Acura.”
“We are excited to be partnered with Pfizer to bring Oxecta to patients who need opioids to manage their pain,” said Robert Jones, interim president and chief executive officer of Acura Pharmaceuticals, Inc. ”Acura is focused on developing technologies that are intended to potentially deter abuse and misuse.”
Oxecta is contraindicated in patients with respiratory depression in unmonitored settings and in the absence of resuscitative equipment, in any patient who has or is suspected of having paralytic ileus, in patients with acute or severe bronchial asthma or hypercarbia, and in patients with known hypersensitivity to oxycodone, oxycodone salts, or any components of the product.
Respiratory depression is the primary risk of Oxecta. This is more common in elderly or debilitated patients, in those suffering from conditions such as COPD, severe asthma, or upper airway obstruction, or following large initial doses of opioids given to non-tolerant patients.
Oxecta contains oxycodone HCl, an opioid agonist and a schedule II controlled substance. Such drugs are sought by drug abusers and people with addictions. Oxecta can be abused in a manner similar to other opioids and narcotics. This should be considered when prescribing or dispensing oxycodone HCl in situations where the physician or pharmacist is concerned about an increased risk of misuse or abuse.
Oxecta may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death. It should not be given to anyone other than the individual for whom it was prescribed. Keep Oxecta in a locked cabinet, drawer or medicine safe so that it will not be stolen.
There is no evidence that Oxecta has a reduced abuse liability compared to immediate-release oxycodone. Take each Oxecta tablet with enough water to ensure complete swallowing immediately after placing in the mouth, and it must be swallowed whole. As Oxecta is not amenable to crushing and dissolution, do not use Oxecta in nasogastric, gastric or other feeding tubes as it may cause obstruction of feeding tubes.
Pfizer, strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals and its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and commercialization of product candidates intended to potentially deter abuse and misuse utilizing its proprietary Aversion and Impede technologies.